SCHEDULE: Yun Yao Reports Ownership Stake in Indaptus Therapeutics
Schedule 13D Amendment
Yun Yao discloses a 31.51% beneficial ownership stake in Indaptus Therapeutics, Inc. following a dilution event.
Summary
- Yun Yao maintains beneficial ownership of 41,991,000 shares of Indaptus Therapeutics, Inc. common stock.
- The reported ownership percentage is 31.51% based on 133,242,324 total outstanding shares as of June 24, 2026.
- The filing serves as an amendment to report a decrease in ownership percentage due to the issuer's recent private placement on June 17, 2026.
- The reporting person did not acquire or dispose of any shares during the period covered by this amendment.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral administrative filing; it confirms the reporting person's continued commitment to the company despite minor dilution.
Positives
- The reporting person maintains a significant long-term equity position of 41,991,000 shares.
Negatives
- The reporting person's ownership percentage has been diluted due to the issuer's recent issuance of additional common stock.
Risks
- Potential for further dilution of existing shareholders if the issuer continues to issue additional equity to fund operations.
Future Outlook
No specific forward-looking guidance provided regarding the issuer's operations; the filing is strictly a disclosure of ownership status.
Industry Context
StockSavvy.ai notes that significant ownership stakes in small-cap biotech firms often signal long-term investor confidence, though frequent dilution events are common in this sector as companies raise capital to fund clinical trials.
Comparison to Industry Standards
- The reporting person's 31.51% stake represents a significant concentration of ownership, which is common for early-stage biotech investors who participate in private placements.
- The dilution event is consistent with standard capital-raising activities for clinical-stage pharmaceutical companies.
Stakeholder Impact
- Existing shareholders experience dilution due to the increase in total outstanding shares.
Next Steps
- Continued monitoring of the issuer's capital structure and potential future equity offerings.
Key Dates
| Date | Description |
|---|---|
| 2026-03-19 | Securities Purchase Agreement date. |
| 2026-03-23 | Closing date of the initial transaction. |
| 2026-03-30 | Initial Schedule 13D filing date. |
| 2026-04-29 | Amendment No. 1 filing date. |
| 2026-06-17 | Issuer private placement date causing dilution. |
| 2026-06-24 | Date of event requiring filing and Form 8-K issuance. |
| 2026-06-26 | Signature date of Amendment No. 2. |
Keywords
Indaptus Therapeutics, Schedule 13D, Yun Yao, Beneficial Ownership, Equity Dilution, Biotech
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.